Skip to main content
. Author manuscript; available in PMC: 2020 Oct 13.
Published in final edited form as: Am J Hematol. 2018 Sep 26;93(11):1394–1401. doi: 10.1002/ajh.25261

Figure 1.

Figure 1.

Outcomes for patients treated with front-line ibrutinib. (A) Progression free survival (PFS) stratified by del(17p13) status. (B) Overall survival (OS) stratified by del(17p13) status. (C) PFS stratified by age. (D) OS stratified by age. (E) PFS in “FCR-ideal” patients (del17p absent, TP53 mutation absent, IGHV mutated, age <65)